Sepsis is a lethal disease in Australia and globally. There has never been a greater need to develop a test that can provide a rapid diagnosis.
This involves identifying and prioritising candidate antigens for vaccine development, determining the optimal formulation and delivery of vaccine antigens, and developing assays to measure vaccine-induced immune responses that can be used in vaccine development and clinical trials.
Studies focus on several leading candidate antigens (AMA1, EBAs, PfRh, MSP2), and also aims to identify and characterise other antigens that could be developed as vaccines.
Work is also undertaken on vaccine approaches to induce potent protective immune responses.
For any general enquiries relating to this project, please contact:
Deputy Director (People); Head of Malaria Research: Immunity, Vaccines and New Therapies Laboratory; Adjunct Professor Monash University